| Name | Clinofibrate |
| Description | Clinofibrate (Lipoclin)(IC50 of 0.47 mM), a lipid-lowering agent, inhibits hydroxymethylglutaryl coenzyme A reductase (HMGCR). It is utilized to control high cholesterol and triacylglyceride levels in the blood. |
| In vitro | In the treatment of arteriosclerosis in rats, Clinofibrate significantly reduces high plasma cholesterol levels. When used in CAPD patients, it effectively decreases very low-density lipoprotein levels. Typically, Clinofibrate (600 mg/daily) reduces serum triglycerides by 36% and very low-density lipoprotein triglycerides by 48%. Additionally, it ameliorates abnormalities in low-density and high-density lipoprotein compositions, markedly increasing the content of high-density lipoprotein cholesterol. |
| In vivo | Clinofibrate, with an IC50 of 40 μM, acts on the activity of human liver 3α-hydroxysteroid dehydrogenase. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 87 mg/mL (185.67 mM), Sonication is recommended. Ethanol : 87 mg/mL (185.67 mM), Sonication is recommended.
|
| Keywords | S8527 | S 8527 | Inhibitor | inhibit | HMGCR | HMGCoAReductase | HMG-CoA Reductase (HMGCR) | HMGCoA Reductase | Clinofibrate | Autophagy |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Autophagy Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Anti-Cancer Approved Drug Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Hypertension Compound Library |